Uveitis as a class effect of Bruton tyrosine kinase inhibitors: ibrutinib and zanubrutinib ocular toxicity.
Oliver Beresford, Ze Yan Ooi, Ayad Al-Bermani
✦ AI-curated · Sources linked
Case in brief
A man in his early 50s with Waldenström macroglobulinaemia developed posterior uveitis while on ibrutinib, characterized by vitreous and retinal infiltrates. The condition resolved after discontinuation of ibrutinib, with recurrence upon re-challenge. Switching to zanubrutinib led to severe panuveitis and keratitis, which also resolved after stopping the medication, suggesting a class effect of BTK inhibitors on ocular health.
Diagnostic / clinical pearl
Clinicians should be aware of the potential for ocular toxicity, including uveitis, in patients treated with Bruton tyrosine kinase inhibitors, particularly if they have a history of sensitivity to these agents.
Why it matters
This case highlights the need for careful monitoring of ocular symptoms in patients receiving BTK inhibitors, as they may experience significant inflammatory reactions.